Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Oct 3, 2008

Arriva Pharmaceuticals : Protein Production Patent

1 October 2008 - Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti-inflammatory therapies, announced that it had been granted a patent in the U.S. for methods to produce certain proteins in yeast. Among the proteins whose production is covered by the patent (United States Patent 7,419,801) is recombinant alpha 1-antitrypsin (rAAT), the protein used in Respriva, the companys lead product.

This patent extends our patent portfolio and strengthens our intellectual property estate for Respriva, said Sue Preston, chief executive officer of Arriva. As we move forward with the development of Respriva, we have multiple competitive advantages that leave us well positioned in the global market.

Respriva is an inhaled rAAT. Arriva is currently conducting clinical trials with Respriva as replacement therapy in hereditary emphysema (HE). Patients with HE have a congenital deficiency in naturally occurring alpha 1-antitrypsin (AAT). Respriva also has the potential to ameliorate lung disease in other indications, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis... [PDF] Arriva Pharmaceuticals' Press Release -